AC-0682 by Accutar Biotechnology for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AC-0682 overview

AC-0682 is under development for the treatment of estrogen receptor positive/human epidermal growth factor 2 negative (ER/HER2) locally advanced or metastatic breast cancer. It is administered by oral route in the for of capsule. The drug candidate is a heterobifunctional PROTAC (proteolysis-targeting chimera) which acts by targeting estrogen receptor (ER) alpha and cereblon (CRBN). It is being developed based on artificial intelligence (AI) technology platform.

Accutar Biotechnology overview

Accutar Biotechnology (Accutar Biotech) is a pharmaceutical drug development company. The company specializes in drug development for breast cancer, prostate cancer, haematology, oncology indications, lung cancer, toxicology, and solid tumors. Its service offerings include clinical trials, drug discovery programs, drug development programs, research and development, and risk management services. The company uses artificial intelligence (AI) platform, data evaluation, deep neural network-based docking platform (orbital), virtual screening, automatic and intelligent lead optimization platform, and deep learning platform for preclinical drug discovery. Accutar Biotech is headquartered in Cranbury, New Jersey, the US.

For a complete picture of AC-0682’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.